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viduals with and without a recorded comorbid diagnosis of malnutrition, dehydra-
tion, UTI and aspiration pneumonia were compared. As there was a significant
interaction between number of comorbidities and hospital charge in the UTI and
pneumonia sample, an analysis of covariance (ANCOVA) model was employed to
adjust the UTI and pneumonia analyses for this influence. The model was adjusted
for complication diagnosis as a factor and both 1) number of comorbidities, and 2)
complication diagnosis and number of comorbidities interaction as covariates.
RESULTS: The most common complications reported in patients with a recorded
diagnosis of dysphagia were UTI (27%, n3424), pneumonia (26%, n3348), dehy-
dration (12%, n1507), and malnutrition (8%, n1027). Dysphagia patients with
complications had significantly higher mean hospital charges than those without
the complications UTI ($35,358 vs. $30,373, p0.001), pneumonia ($33,085 vs.
$31,184, p0.001), dehydration ($28,093 vs. $20,850, p0.001), and malnutrition
($37,192 vs. $34,747, p0.001), and MS ($32,406 vs. $23,726, p0.001).
CONCLUSIONS: Our results demonstrate that having to treat the complications of
dysphagia adds significantly to the cost of hospital care. Proactive management of
patients with dysphagia may confer substantial savings to hospitals.
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OBJECTIVES: To investigate the cost and incidence of adverse gastrointestinal (GI)
events caused by bisphosphonate therapy in Taiwan. METHODS: We conducted a
retrospective cohort study based on the National Health Insurance Research data-
base in Taiwan from 2005 to 2009. The inclusion criteria for the study cases were
patients 1) who sought inpatient or outpatient care for gastrointestinal problems
with ICD9-CM codes of GI-related diagnosis within 4 months after the initiation of
filling bisphosphonate prescription (the index date) for bisphosphonate, and 2)
who have no prior history of GI treatment 90 days before the index date. The costs
and incidence associated with GI adverse events were assessed based upon sur-
vival analysis and generalized linear models. RESULTS: A total of 114,086 patients
were included in this study. The GI incidence rate was lower in the group treated
with risedronate (16%) than alendronate (25%). The average time of onset of GI
event was longer after taking risedronate (1.6 months) than taking alendronate (1
month). The average direct medical cost associated with a GI event was $3147(USD)
and $6235 (USD) in group treated with risedronate and alendronate, respectively.
The distribution of costs of GI events was physician consultation fees (35%), exam-
ination fee (10%), drug costs including proton pump inhibitors (22%), H2-blocker
(14%), cytoprotectants (7%) and other GI related costs (12%). CONCLUSIONS: Bis-
phosphonate treatment of osteoporosis may involve adverse GI events and their
associated medical costs should be taken into account when evaluate cost-effec-
tiveness of treatment for osteoporosis.
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OBJECTIVES: Dysphagia has been previously shown to increase hospital length of
stay (LOS) (Altman et al, 2010). The objective of this study was to quantify the
difference in hospital charges between patients identified with and without dys-
phagia among commonly associated neuromuscular, neurologic and cardiovascu-
lar diseases. METHODS: Using 2008 Health Care Utilization Project (HCUP) data,
individuals with a hospital discharge diagnosis of stroke, Alzheimer’s disease (AD),
ALS, dementia, heart failure (HF), multiple sclerosis, cerebral palsy, Huntington’s
disease, and Parkinson’s disease (PD) were identified using ICD-9 CM diagnosis
codes. Within each disease state, the mean (10% trimmed) hospital charges for
individuals with a recorded diagnosis of dysphagia (ICD-9: 438.82, 787.2-787.29)
were compared to those without dysphagia. An analysis of covariance (ANCOVA)
model was employed to account for potential impact of comorbidities on hospital
charges. The model was adjusted for dysphagia diagnosis as a factor and both 1)
number of comorbidities, and 2) dysphagia diagnosis and number of comorbidities
interaction as covariates. RESULTS: Dyphasgia was most commonly diagnosed in
patients with stroke (41.2%, n11,736), dementia (0.6%, n1,126), AD (0.4%, n489)
and HF (0.3%, n2,087). Cerebral palsy, PD, HD, and ALS were excluded from the
analysis due to small dysphagia sample (n10). Patients with dysphagia demon-
strated higher mean hospital charges compared with non-dysphagia patients for
stroke ($32,531 vs. $26,004, p0.001), dementia ($26,836 vs. $23,445, p0.001), AD
($25,431 vs. $22,915, p0.001), HF ($30,686 vs. $26,984, p0.001), and MS ($32,406 vs.
$23,726, p0.001) adjusted for number of comorbidities. The magnitude and direc-
tion of the association between dysphagia and hospital charges were consistent in
both the bivariate and multivariate analyses. CONCLUSIONS: Our results demon-
strate that patients with conditions that are complicated by dysphagia cost hospi-
tals significantly more than similar patients without dysphagia and management
of these patients can avert significant costs.
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OBJECTIVES: Generic prescribing is important in South Africa. Many medical aid
schemes will only reimburse the cost of the generic product, and a co-payment is
required if a patient wants to use the originator product. The primary aim of this
study was to investigate originator versus generic prescribing focussing on proton
pump inhibitors (PPIs). METHODS: Prescription data were obtained from a private
medical aid administrator in South Africa. The data covered 2010 and included
medication, procedures and devices (a total of 2126264 records). For the purpose of
this study, only PPI medicine items were extracted and analysed (MIMS category
12.4.4). Basic descriptive statistics were calculated. RESULTS: A total of 20537 PPIs
were prescribed (only 18.56% on the chronic option of the medical aid schemes).
Five different PPI active ingredients were prescribed to 7060 patients (50.88% fe-
male patients). Omeprazole was the most often prescribed PPI, accounting for half
of all PPI prescribing (50.78%), followed by esomeprazole (19.83%) and lansoprazole
(18.04%). Eight different trade names of omeprazole were prescribed (one generic
product accounted for 56.00% of all omeprazole prescriptions and 56.08% of the
cost of omeprazole prescriptions). The originator product only accounted for 1.75%
of omeprazole prescribing frequency and 3.07% of prescribing cost. Only one trade
name of esomeprazole was prescribed (no generic equivalents) and nine trade
names of lansoprazole (the originator accounted for 1.43% of prescribing frequency
and 2.51% of cost). On average, esomeprazole had the highest average cost of
R308.97, followed by rabeprazole (R236.58). Both these products do not have generic
equivalents on the South African market. CONCLUSIONS: Further studies that
include dosage forms and prescribed daily doses (PDDs) should be conducted
alongside cost analyses. A clear difference between the prescribing and cost of
originator versus generic prescribing was detected in this study.
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OBJECTIVES: To determine the cost range for different forms of antyhelicobacter
therapy (first and second line) of the working age patients with gastric and duode-
num ulcer in Ukraine. METHODS: Different variants of (triple and quadrotherapy)
of traditional schemes of antihelicobacter therapy, recommended by “Maastriht”
(2005) have been used in the research. When treatment course costs determination
for antihelicobacter therapy for one patient, the expenses only for drugs included
in the tested schemes have been taken. The prices for drugs have been taken from
the information system “Medicinal preparations”, Morion Company (August 2010).
The currency rate to dollar (USA) on August 31, 2010 was 7,89:1. Medicinal prepa-
rations with minimal and maximal costs for the disease treatment course have
been included for the costs range evaluation for the course of antihelicobacter
therapy of the first and second line for one patient. RESULTS: The costs range of
antihelicobacter therapy of the first and second line in Ukraine is rather large, $
5,71– $ 238,55 and $ 5,78 – $ 149,26, respectively. It is connected with big difference
between the cost of original and generic drugs, included into antihelicobacter ther-
apy scheme. CONCLUSIONS: The cost for antihelicobacter gastric ulcer and duo-
denal therapy course with the use of original and foreign generics can be rather
high in Ukraine. In connection with it, when drugs choosing it is reasonable to use
pharmacoeconomics research results, that will help to optimize the state, insuar-
ing componies and patients expenses for the disease treatment.
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OBJECTIVES: To compare health care costs between patients who switched from a
branded proton pump inhibitor (PPI) to a generic PPI and vice versa.METHODS:We
conducted a retrospective database analysis using commercial enrollees from a
large US health plan from February 2008 to March 2010. Continuously eligible adult
patients who had gastroesophageal reflux disease (GERD) or GERD-related condi-
tions, and evidence of PPI use during February 2009 to September 2009 were in-
cluded. The index PPI was defined as the first PPI prescribed during the identifica-
tion period. The two cohorts in this study included patients who switched from a
generic PPI to a branded index PPI versus patients who switched from a branded
index PPI to a generic index PPI. Risk adjustment was performed using propensity
score matching. We controlled for age, gender, region, GERD severity, plan, pre-
index Quan-Charlson comorbidity score (CCI), baseline daily average consumption
(DACON), and baseline costs and utilization.RESULTS:A total of 9881 patients from
each cohort were matched after propensity score matching. During the 6 months
after the switch, there were no statistically significant differences between the two
cohorts in terms of office visit costs, outpatient costs, emergency services costs,
inpatient costs, and other costs., However, patients who switched to a generic PPI
had lower pharmacy costs ($1919 vs. $2306, p0.001). CONCLUSIONS: Although
pharmacy costs are slightly lower for patients who switched from a branded to a
generic PPI, there were no significant differences in other health care costs such as
for office visits, emergency room services, and inpatient visits.
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